Skip to main content
. Author manuscript; available in PMC: 2020 Jul 1.
Published in final edited form as: AJNR Am J Neuroradiol. 2019 Jun 27;40(7):1132–1139. doi: 10.3174/ajnr.A6110

Table 2.

Overall survival stratified by progression status at week 16.

Sequence Progression by week 16? Progression by week 16? (R vs NR-NP)
No Yes R NR-NP P
N (%) Median OS (days) (95% CI) N (%) Median OS (days) (95% CI) N (%) Median OS (days) (95% CI) N (%) Median OS (days) (95% CI) N (%) Median OS (days) (95% CI)
2D 36 (63%)
448
(321, 660)		 21 (37%)
212
(170, 268)		 16 (28%)
437
(319, 971)		 20 (35%)
451
(232, 687)		 21 (37%)
212
(170, 268)
P<0.0001 (N=57) P=0.73: R vs NR-NP
dT1 31 (54%)
434
(319, 676)		 26 (46%)
221.5
(196, 309)		 23 (40%)
448
(319, 687)		 8 (14%)
362.5
(127, -)		 26 (46%)
221.5
(196, 309)
P=0.006 (N=57) P=0.61: R vs NR-NP